Martin J. Blaser
Martin J. Blaser(born 1948)  is the Muriel G. and George W. Singer Professor of Translational Medicine, Director of the NYU Human Microbiome Program, former Chair of the Department of Medicine, and Professor of Microbiology at New York University School of Medicine. In 2013 he was elected to the American Academy of Arts and Sciences. He is an established researcher in microbiology and infectious diseases. Blaser's work has focused on Helicobacter pylori, Campylobacter species, Salmonella Bacillus anthracis, and more recently on the human microbiome.
Education, early work, recent service
Blaser obtained his undergraduate education from the University of Pennsylvania in 1969, graduated from the New York University School of Medicine in 1973, and did his post-graduate training at the University of Colorado School of Medicine from 1973 to 1979. Blaser was an Epidemic Intelligence Service Officer at the Centers for Disease Control and Prevention from 1979 to 1981.
In 2005, Blaser was elected the President of the Infectious Diseases Society of America. He has served the National Institutes of Health on the Board of Scientific Counselors of the National Cancer Institute (2005–2010; Chair 2009–2010), and on the Advisory Board for Clinical Research (2009–2013; Chair 2012-2013). In 2011, he was elected into the National Academy of Medicine (formerly Institute of Medicine), in recognition of professional achievement and commitment to service in medicine and health.
In 2014, he was the Kinyoun Lecturer at the National Institute for Allergy and Infectious Diseases (NIAID) at NIH, and received the Alexander Fleming Award for lifetime achievement from the Infectious Diseases Society of America.
In 2015, he was selected to be in the TIME 100 Most Influential People in the world, He serves on the Advisory Council of the National Center for Complementary and Integrative Health (NCCIH) of the National Institutes of Health. He was appointed as the Chair of the President's Advisory Council on Combating Antibiotic-Resistant Bacteria (CARB) for a term from 2015-2019.
Blaser is best known for his studies of Helicobacter pylori and its relationship with human diseases. His work helped establish the role of H. pylori in the causation of gastric cancer, the second leading cause of cancer death in the world. Studies of the diversity of H. pylori lead him to identify the CagA protein and its gene in 1989, which broadened understanding of H. pylori interactions with humans. His team found that cagA+ strains induced enhanced host responses, development of atrophic gastritis, gastric cancer, and peptic ulcer disease, compared to cagA− strains, and that cagA+ strains signal human gastric cells differently from cagA− strains, and affect gastric physiology in markedly different ways than in the absence of H. pylori. This work led to a general model for the persistence of co-evolved organisms, based on the presence of a Nash equilibrium, and also for the relationship of persisting microbes to cancer, and age-related mortality.
Beginning in 1996, he hypothesized that H. pylori strains might have benefit to humans as well as costs. Despite considerable and ongoing skepticism by the community of H. pylori investigators, Blaser and his colleagues progressively developed a body of research that provided evidence that gastric colonization by this organism provided protection against the esophageal diseases of GERD (gastroesophageal reflux disease), Barrett's esophagus, and esophageal adenocarcinoma, work that has been confirmed by independent investigators. His work has suggested a benefit of H. pylori against such early life illnesses as childhood diarrhea and asthma. This work is consistent with the hypothesis that H. pylori is an ancient, universal inhabitant of the human stomach that has been disappearing as a result of 20th century changes in socio-economic status, including the use of antibiotics.
In 1998, Blaser created the term acagia, to indicate a susceptibility for esophageal diseases in persons not carrying cagA+ H. pylori strains. Since then, acagia has come to reflect the rise in other diseases associated with the loss of cagA+ H. pylori, and may become a metaphor for the disappearance of members of the human microbiome that have symbiotic roles. In 2009, with Stanley Falkow, he hypothesized that human microecology is rapidly changing with potentially substantial consequences. He envisioned a step-wise (generational) change to explain the epidemic rise of such diseases as childhood-onset asthma and obesity. Blaser has proposed that greater understanding of our indigenous (and sometimes disappearing) microbiota can lead to improvements in human health.
He has proposed that the routine use (and overuse) of antibiotics in young children may be causing collateral damage, with extinctions of our ancient microbiota at critical stages of early life. This scenario may be contributing to the risk of epidemic metabolic, immunologic, and developmental disorders. Studies in mice have contributed strong support to these hypotheses., and on-going work in children with reference to many diseases, asthma, show the importance of early life microbiome perturbation in increasing risk.
Blaser has written a book for general audiences, Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues, about the degradation of human's internal microbial ecosystem as a result of modern medical practices. It was published by Henry Holt and Co. in April 2014, and is being translated into 16 languages [number of translation needs reference].
- NYU Blaser Lab Website http://www.med.nyu.edu/medicine/labs/blaserlab/
- Blaser MJ, Berkowitz ID, LaForce FM, Cravens J, Reller LB, Wang WLL. Campylobacter enteritis: Clinical and epidemiologic features. Annals of Internal Medicine 1979; 91:179 185.
- CDC Website http://www.cdc.gov/
- "The twists and turns of fate", The Economist. http://www.economist.com/node/11959214. "Germs are Us. Bacteria makes us sick. Do they also keep us alive?" The New Yorker by Michael Specter. October 22, 2012. http://www.newyorker.com/reporting/2012/10/22/121022fa_fact_specter?currentPage=all
- Blaser MJ. The bacteria behind ulcers. Scientific American February, 1996; 274:104–109.
- Atherton JC, Blaser MJ. Co-adaptation of Helicobacter pylori and humans: ancient history, modern implications. Journal of Clinical Investigation 2009; 119:2475–87.
- Nomura A, Stemmerman GN, Chyou P-H, Kato I, Pérez-Pérez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma in a population of Japanese-Americans in Hawaii. New England Journal of Medicine 1991; 325:1132–1136.
- Blaser MJ, Pérez-Pérez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, Stemmermann GN, Nomura A. Infection with Helicobacter pylori strains possessing cagA associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Research 1995; 55:2111–2115.
- Blaser MJ, Kirschner D. The equilibria that permit bacterial persistence in human hosts. Nature 2007; 449:843–849.
- Blaser MJ. Understanding microbe-induced cancers. Cancer Prevention Research 2008; 1:15–20.
- 13. Blaser MJ, Webb GF. Host demise as a beneficial function of indigenous microbiota in human hosts. mBio 2014; 5:1-9. doi: 10.1128/mBio.02262-14.
- Blaser MJ. An endangered species in the stomach. Scientific American, February 2005; 292:38–45.
- Blaser MJ. Disappearing microbiota: Helicobacter pylori protection against esophageal adenocarcinoma. Cancer Prevention Research 2008; 1:308–311.
- Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Reports 2006; 7:956–960.
- Blaser MJ, Falkow S. What are the consequences of the disappearing human microbiota? Nature Reviews Microbiology 2009; 7:887–894.
- Blaser MJ. Harnessing the power of the human microbiome. Proceedings of the National Academy of Sciences, USA. 2010; 107:6125–6126.
- Blaser MJ. Antibiotic overuse: Stop the killing of beneficial bacteria. Nature 2011; 476:393–394.
- Cho I, et al. Early-life antibiotics alter the murine colonic microbiome and adiposity. Nature 2012; 488:621-626. [PMID 22914093]
- Cox LM, et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014 Aug 14;158(4):705-21. doi: 10.1016/j.cell.2014.05.052. PMID 25126780
- Nobel Y et al. Metabolic and metagenomic outcomes from early-life pulsed antibiotic treatment. Nature Communications 2015; 6:7486.
- Trasande L, Blustein J, Liu M, Corwin E, Cox LM, Blaser MJ. Infant antibiotic exposures and early life body mass. International Journal of Obesity 2013; 37:16-23.
- Arrieta M-C et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science Translational Medicine 2015; 7:307ra152.
- Dominguez-Bello MG, Blaser MJ. Asthma: Undoing millions of years of co-evolution in early life? Science Translational Medicine 2015; 7:307fs39.
- "Drugs: Gut Response". Nature Reviews http://www.nature.com/nature/journal/v508/n7495/full/508182a.html
- "Antibiotics and Collateral Damage". By Allison Mather, Science May 2, 2014 Volume 344, no 6183 pp.472-473. http://www.sciencemag.org/content/344/6183/472.1.full.pdf
- "Save the Microbes: How antibiotics are making us sick". Wired Magazine, March 2014. http://www.summarizedreading.com/2014/04/save-microbes-how-antibiotics-are.html#!/2014/04/save-microbes-how-antibiotics-are.html
- "Personal Health: We Are Our Bacteria". By Jane Brody, Well Blog, New York Times, July 14, 2014 http://well.blogs.nytimes.com/2014/07/14/we-are-our-bacteria/